CN102846641A - Compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry - Google Patents

Compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry Download PDF

Info

Publication number
CN102846641A
CN102846641A CN201210358603XA CN201210358603A CN102846641A CN 102846641 A CN102846641 A CN 102846641A CN 201210358603X A CN201210358603X A CN 201210358603XA CN 201210358603 A CN201210358603 A CN 201210358603A CN 102846641 A CN102846641 A CN 102846641A
Authority
CN
China
Prior art keywords
parts
sodium
sodium powder
potassium
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201210358603XA
Other languages
Chinese (zh)
Other versions
CN102846641B (en
Inventor
陈益德
秦斌
胡学全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHONGQING JINBANG ANIMAL PHARMACEUTICAL Co Ltd
Original Assignee
CHONGQING JINBANG ANIMAL PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHONGQING JINBANG ANIMAL PHARMACEUTICAL Co Ltd filed Critical CHONGQING JINBANG ANIMAL PHARMACEUTICAL Co Ltd
Priority to CN 201210358603 priority Critical patent/CN102846641B/en
Publication of CN102846641A publication Critical patent/CN102846641A/en
Application granted granted Critical
Publication of CN102846641B publication Critical patent/CN102846641B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry. The compound sulfachlorpyridazine sodium powder comprises the following components by weight: 60-65 parts of sulfachloropyridazine sodium, 2-4 parts of indometacin potassium, 10-25 parts of suspending agents, 2-4 parts of flavoring agents and acceptable carriers accounting for parts added to be 100 parts. The compound sulfachlorpyridazine sodium powder has definite effect on pasteurellosis of various animals and is suitable for being popularized and applied to breeding of livestock and poultry. According to the compound sulfachlorpyridazine sodium powder, the sulfachloropyridazine sodium and the indometacin potassium are compatible for use, so that when antibacterial and anti-inflammatory effects are achieved, the indometacin potassium serving as the antibacterial synergist of the sulfachloropyridazine sodium can have an synergistic effect to strengthen the drug effect of the main drug. The compound sulfachlorpyridazine sodium powder can be taken orally or mixed in feeds or drinking water, is good in absorption and safe in usage, does not produce drug resistance easily, can be used for health protection, prevention and treatment for a long time, has good palatability, flowability and suspension water-soluble performance, and is various in clinical dosing mode and convenient to dose.

Description

A kind of Compound Sulfachorpyrdazine Sodium Powder for control poultry pasteurella infection
Technical field
The present invention relates to a kind of Compound Sulfachorpyrdazine Sodium Powder, also relate to the medicine of control poultry pasteurella infection.
Background technology
The Prinzone (Squibb) antimicrobial spectrum is similar to sulfamonomethoxine, is one of the strongest sulphonamides of vivo bacteria corrosion action, and most of gram positive bacterias and negative bacterium are had stronger inhibitory action, and it is slower that antibacterial produces drug resistance to this medicine.Blood drug level is high, and the acetyl rate is low, is difficult for producing crystalluria.
Bacillus pasteurii disease is a kind of septic infectious disease of the many animals that caused by pasteurella multocida.When weather, seasonal variations, long-distance transport and the factors such as parasitic infection, malnutrition caused the animal body resistance to reduce, health is carried disease germs, and existing pasteurellosis bacillus will become strong toadstool and cause autogenous infection in animal breath road and the tonsil.In addition can be owing to the feedstuff that pollutes, water, air, utensil etc. cause exogenous infection through digestive tract, respiratory tract, wound.Because the infective agent ubiquity, the normal acute attack of primary disease, the sick fowl of acute can be without any symptom, several lower wings of flapping suddenly death that falls down to the ground, and the morbidity animal is in the majority, comparatively serious age with the children, and case fatality rate is high.
The medicine that needs the more definite control poultry pasteurella infection of a kind of effect in the prior art.Simultaneously, do not prevent and treat the Prinzone (Squibb) powder preparation of poultry pasteurella infection in the prior art yet.
Summary of the invention
Main purpose of the present invention provides a kind of Compound Sulfachorpyrdazine Sodium Powder for control poultry pasteurella infection.
The technical solution adopted in the present invention is: a kind of Compound Sulfachorpyrdazine Sodium Powder for control poultry pasteurella infection is characterized in that: the component that comprises following weight ratio:
Figure BDA00002183094400011
Figure BDA00002183094400021
Further, described correctives is sucrose and/or saccharin sodium.
Further, described suspending agent is one or more in silicon Bentonite, sodium citrate, the sodium carboxymethyl cellulose.
Further, described suspending agent is the mixture of 5~10 parts of silicon Bentonite, 5~10 parts of sodium citrates, 3~5 parts of sodium carboxymethyl cellulose.
Further, described acceptable carrier is anhydrous glucose or soluble starch.
The preparation method of Compound Sulfachorpyrdazine Sodium Powder of the present invention comprises the steps:
A, the suspending agent of getting recipe quantity are pulverized, and cross 80 eye mesh screens after pulverizing, and then mix, check the opaque uniformity without decorative pattern without mottle, get the A powder, for subsequent use; Common incorporation time is 15min approximately;
B, the Prinzone (Squibb) of getting recipe quantity, indomethacin potassium and correctives are pulverized, and cross 80 eye mesh screens after pulverizing, and then mix, and the inspection opaque uniformity without mottle, gets the B powder without decorative pattern; Common incorporation time is 15min approximately;
C, above-mentioned B powder added in the A powder by the equivalent method of progressively increasing stir, then add acceptable other carrier of capacity and continue to mix, check and confirm that the opaque uniformity crosses 80 eye mesh screens without decorative pattern after without mottle, and get final product; Common incorporation time is 15min approximately.
During packing, can fill in vinyon bottle, polyethylene plastic bag, loading amount comprises 100g, 200g, 500g etc.
Theoretical foundation of the present invention may be: technical scheme of the present invention has better been brought into play the effect of indomethacin potassium: indomethacin (Indomethacin) has obvious potent effect to some antibiotic or antimicrobial drug.Because lung tissue is tissue basophil, when pulmonary is inflamed, the sulfa drugs of some antibiotic of indomethacin portability such as high dose preferentially arrives infection site, and high concentration is gathered in the inflammatory tissue cell peripheral, indomethacin can make sulfa drugs concentration in infected tissue improve 4~8 times, and the anti-infectives use amount can reduce by half even can only be 1/4 of positive usual amounts after the coupling.This Synergistic Mechanisms is different from the mechanism of action of trimethoprim.Indomethacin also has significant antiinflammatory, analgesic and analgesic activity.Its antiinflammation is the strongest in the anti-inflammation drugs.It is to the high febrile illness antipyretic and anti-inflammatory of pig, the chicks thoracic cavity infection, duck infectious bronchitis and poultry pneumonia, hydrothorax and Combination pneumonia have significant adjuvant treatment effect, and this may have obviously potent relevant with antiinflammation with indomethacin.
The present invention shows following technical advantage in practice:
1, the Bacillus pasteurii disease of many animals there is definite curative effect, is suitable in livestock culture, the promoting the use of.The present invention adopts Prinzone (Squibb) and indomethacin potassium compatibility to use, and indomethacin potassium can produce the drug effect that synergism strengthens principal agent as the Trimethoprim of Prinzone (Squibb) in anti-inflammation.Oral, mixed feeding, drinking-water absorb good and are difficult for producing drug resistance, and safety is used in long-term care prevention and treatment.
2, the Compound Sulfachorpyrdazine Sodium Powder of novel process technology preparation has good palatability, flowability and suspendible water solublity, guarantees that this product clinical administration mode is various and convenient.Correctives can be covered the bitterness of Prinzone (Squibb), indomethacin potassium fully, can be directly oral; The adjuvant of the selected suitable particle diameter of prescription makes finished product that good flowability be arranged, and is convenient to even mixing, and mixed fodder is fed also very safe; Simultaneously, this product also is dry suspension, easily topple over after the dissolving, sedimentation slowly, jolting can redispersion gently after the sedimentation, and the size of the suspended particles after the dissolving remains unchanged in long-term the storage in water.This has guaranteed again effectiveness and safety that drinking-water uses.
The specific embodiment
The principal agent Prinzone (Squibb) that uses among the embodiment (anhydride meter content is 99.8%) is purchased from city far away, Zhuhai medication chemistry company limited; Indomethacin potassium (anhydride meter content is 99.1%) is purchased from Ou Yi Shi Pharmaceutical Group Pharmaceutical Co; Soluble starch, anhydrous glucose, sucrose and saccharin sodium are purchased from Henan navigator's chemical products company limited; Silicon Bentonite, sodium citrate, sodium carboxymethyl cellulose (AR) are purchased from Jizhou City China thing Science and Technology Ltd. of Hang Seng.
Embodiment one
1, prescription
Prinzone (Squibb) 60g, indomethacin potassium 2g, silicon Bentonite 5g, sodium citrate 5g, sodium carboxymethyl cellulose 3g, saccharin sodium 2g, soluble starch 23g.
2: preparation method
The first step: silicon Bentonite, sodium citrate, the sodium carboxymethyl cellulose of getting recipe quantity are pulverized, and cross 80 eye mesh screens after pulverizing, and then mix 15min, get without the A powder of decorative pattern without mottle, and be for subsequent use;
Second step: Prinzone (Squibb), indomethacin potassium and the saccharin sodium of getting recipe quantity are pulverized, and cross 80 eye mesh screens after pulverizing, and then mix 15min, get without the B powder of decorative pattern without mottle, and be for subsequent use;
The 3rd step: above-mentioned B powder added in the A powder by the equivalent method of progressively increasing stir, then add the capacity soluble starch and continue to mix 15min.Check to confirm that the opaque uniformity crosses 80 eye mesh screens without decorative pattern after without mottle, namely get Compound Sulfachorpyrdazine Sodium Powder.
Embodiment two
1, prescription
Prinzone (Squibb) 62.5g, indomethacin potassium 3g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 12.5g.
2: preparation method: identical with embodiment 1 described method, only the correctives saccharin sodium is changed to sucrose, other carrier soluble starch is changed to anhydrous glucose.
Embodiment three
1, prescription
Prinzone (Squibb) 65g, indomethacin potassium 4g, silicon Bentonite 10g, sodium citrate 10g, sodium carboxymethyl cellulose 5g, sucrose 4g, anhydrous glucose 2g.
2: preparation method: identical with embodiment 1 described method, only the correctives saccharin sodium is changed to sucrose, other carrier soluble starch is changed to anhydrous glucose.
The stability test of Compound Sulfachorpyrdazine Sodium Powder
1, materials and methods: the Compound Sulfachorpyrdazine Sodium Powder of getting embodiment 1-3, carry out hot and humid high light according to an appendix medicine stability of " Chinese veterinary pharmacopoeia " version in 2010 experimental technique and accelerate experiment, press commercially available back, in the medicine stability experimental box (Chongqing immortality experimental apparatus factory) of 40 ± 2 ℃ of temperature, relative humidity 75 ± 5%, illumination 4500 ± 500LX, placed 6 months, take a sample respectively once at experimental session the 1st, 2,3,6 the end of month, character, content, granularity, the outward appearance uniformity, settling volume ratio, the redispersibility of powder are investigated.
2, result: as shown in Table 1, Compound Sulfachorpyrdazine Sodium Powder of the present invention is in accelerated test after 6 months, character, content, granularity, the outward appearance uniformity, settling volume ratio, redispersibility have no significant change, have good stability, meet " Chinese veterinary pharmacopoeia " version in 2010 fully to the quality index requirement of dry suspension.
The acceleration experimental result of table 1, Compound Sulfachorpyrdazine Sodium Powder of the present invention
Compound Sulfachorpyrdazine Sodium Powder is at the veterinary clinic effect
1. materials and methods
1.1 medicine
Compound Sulfachorpyrdazine Sodium Powder of the present invention adopts the embodiment of the invention 2 products.
1.2 case source: the technical staff in the Hechuan, the areas such as Tongliang County, Tongnan gather clinically in pasteurella infection natural occurrence case, are respectively duck infectious bronchitis 337 examples, chicken pneumonia 3625 examples, rabbit snuffles 284 examples, piglet pleuropneumonia 235 examples, chicken cholera 2780 examples, baby swine paratyphoid 332 examples, acute fibrinous pleurisy 101 examples of cattle.
1.3 case diagnosis: with natural cases according to epidemiology, clinical symptoms, pathological change, Laboratory Diagnosed.Analysis-by-synthesis is diagnosed as the pasteurella infection case.
1.4 implementation process: carry out case by the technical staff of this seminar and select and implement to treat, and log.
1.5 the result judges
Usage and dosage: natural cases is used by drinking-water is for oral administration, once measured, every 1kg body weight, pig, cattle 20~30mg are used in conjunction 6; Chicken, duck, rabbit 20~30mg are used in conjunction 4.Observe after one week, pay a return visit and the record state of an illness.
Cure: the complete obiteration of 3~4 future trouble poultrys of medication disease, spirit, body temperature, appetite recover normal, and urine feces is normal.
Effectively: 3~4 future trouble poultrys of medication disease disappears substantially, and spirit, body temperature, appetite make moderate progress, and urine feces is normal.
Invalid: 4 future troubles of medication poultry disease does not disappear, and sb.'s illness took a turn for the worse or dead, and urine stool colour, character are undesired.
2. result: compound sulfamethoxazole methoxy pyridazine injection of the present invention has good therapeutic effect as can be seen from Table 2, the effective percentage such as duck infectious bronchitis, chicken pneumonia, rabbit snuffles, piglet pleuropneumonia, chicken cholera, baby swine paratyphoid, the acute fibrinous pleurisy of cattle are reached more than 96.0%, cure rate is all more than 92%, and chicken cholera, chicken pneumonia are had specially good effect.
Table 2: Compound Sulfachorpyrdazine Sodium Powder clinical therapeutic efficacy statistical table of the present invention
Figure BDA00002183094400061
Compound Sulfachorpyrdazine Sodium Powder of the present invention adopts Prinzone (Squibb) and the composite effect that obtains enhancing evident in efficacy of indomethacin potassium.And the consumption of indomethacin potassium is to need to be strict with in the prescription, can only select at this particular range.
For verifying this technique effect, compare test.
The prescription of Comparative Examples 1: Prinzone (Squibb) 62.5g, indomethacin potassium 1g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 14.5g.
The prescription of Comparative Examples 2: Prinzone (Squibb) 62.5g, indomethacin potassium 6g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 9.5g.
The prescription of Comparative Examples 3: Prinzone (Squibb) 62.5g, indomethacin potassium 10g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 5.5g.
Preparation method is identical with embodiment 1.
Implement 2 product and Comparative Examples 1,2,3 product, the curative effect that is used for the treatment of the pasteurella infection case by same usage and dosage is as shown in table 3, and visible prescription of the present invention has been obtained significant technique effect.
The statistical effect table of table 3 product of the present invention and contrast product clinical treatment chicken pneumonia
Figure BDA00002183094400071

Claims (7)

1. Compound Sulfachorpyrdazine Sodium Powder is characterized in that: the component that comprises following weight ratio:
Figure FDA00002183094300011
2. a kind of Compound Sulfachorpyrdazine Sodium Powder according to claim 1, it is characterized in that: described correctives is sucrose and/or saccharin sodium.
3. a kind of Compound Sulfachorpyrdazine Sodium Powder according to claim 1, it is characterized in that: described suspending agent is one or more in silicon Bentonite, sodium citrate, the sodium carboxymethyl cellulose.
4. a kind of Compound Sulfachorpyrdazine Sodium Powder according to claim 3, it is characterized in that: described suspending agent is the mixture of 5~10 parts of silicon Bentonite, 5~10 parts of sodium citrates, 3~5 parts of sodium carboxymethyl cellulose.
5. a kind of Compound Sulfachorpyrdazine Sodium Powder according to claim 4 is characterized in that: 60 parts of described Prinzone (Squibb)s, 2 parts in indomethacin potassium, 5 parts of silicon Bentonite, 5 parts of sodium citrates, 3 parts of sodium carboxymethyl cellulose, 2 parts of saccharin sodium, 23 parts of soluble starches.
6. a kind of Compound Sulfachorpyrdazine Sodium Powder according to claim 4 is characterized in that: 62.5 parts of described Prinzone (Squibb)s, 3 parts in indomethacin potassium, 7.5 parts of silicon Bentonite, 7.5 parts of sodium citrates, 4 parts of sodium carboxymethyl cellulose, 3 parts of sucrose, 12.5 parts of anhydrous glucose.
7. a kind of Compound Sulfachorpyrdazine Sodium Powder according to claim 4 is characterized in that: 65 parts of described Prinzone (Squibb)s, 4 parts in indomethacin potassium, 10 parts of silicon Bentonite, 10 parts of sodium citrates, 5 parts of sodium carboxymethyl cellulose, 4 parts of sucrose, 2 parts of anhydrous glucose.
CN 201210358603 2012-09-24 2012-09-24 Compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry Expired - Fee Related CN102846641B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201210358603 CN102846641B (en) 2012-09-24 2012-09-24 Compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201210358603 CN102846641B (en) 2012-09-24 2012-09-24 Compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry

Publications (2)

Publication Number Publication Date
CN102846641A true CN102846641A (en) 2013-01-02
CN102846641B CN102846641B (en) 2013-10-16

Family

ID=47393889

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201210358603 Expired - Fee Related CN102846641B (en) 2012-09-24 2012-09-24 Compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry

Country Status (1)

Country Link
CN (1) CN102846641B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105708944A (en) * 2016-03-10 2016-06-29 福建傲农生物科技集团股份有限公司 Pharmaceutical preparation for preventing swine eperythrozoonosis and preparation method and application thereof
CN105920165A (en) * 2016-06-23 2016-09-07 福建傲农生物科技集团股份有限公司 Novel medicine preparation for efficiently preventing and treating pasteurellosis of livestock and poultry and preparation method thereof
CN106692195A (en) * 2016-12-28 2017-05-24 重庆金邦动物药业有限公司 Florfenicol dry suspension agent and preparation method thereof
CN106727578A (en) * 2016-12-22 2017-05-31 保定冀中药业有限公司 Compound Sulfachorpyrdazine Sodium Powder and preparation method thereof
CN107502981A (en) * 2017-08-24 2017-12-22 海盐派特普科技有限公司 A kind of processing technology of down jackets antibacterial protection against the tide eider down

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RALPH D.FEIGIN ETAL: "《Textbook of Pediatric Infectious Diseases》", 31 December 2004 *
徐艳: "吲哚美辛在畜禽疾病中的应用", 《养殖技术顾问》 *
聂斌等: "紫外分光光度法和永停滴定法测定复方磺胺氯达嗪钠粉的含量", 《中国兽药杂志》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105708944A (en) * 2016-03-10 2016-06-29 福建傲农生物科技集团股份有限公司 Pharmaceutical preparation for preventing swine eperythrozoonosis and preparation method and application thereof
CN105920165A (en) * 2016-06-23 2016-09-07 福建傲农生物科技集团股份有限公司 Novel medicine preparation for efficiently preventing and treating pasteurellosis of livestock and poultry and preparation method thereof
CN106727578A (en) * 2016-12-22 2017-05-31 保定冀中药业有限公司 Compound Sulfachorpyrdazine Sodium Powder and preparation method thereof
CN106692195A (en) * 2016-12-28 2017-05-24 重庆金邦动物药业有限公司 Florfenicol dry suspension agent and preparation method thereof
CN107502981A (en) * 2017-08-24 2017-12-22 海盐派特普科技有限公司 A kind of processing technology of down jackets antibacterial protection against the tide eider down

Also Published As

Publication number Publication date
CN102846641B (en) 2013-10-16

Similar Documents

Publication Publication Date Title
CN102846641B (en) Compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry
CN103054808B (en) Tilmicosin dry suspension, method for preparing dry suspension and uses thereof
CN106176617B (en) Amoxicillin soluble powder and preparation method thereof
CN103285374B (en) A kind of Amoxicillin colistin sulphate granule and preparation method thereof
CN101934070A (en) Veterinary antibacterial drug composition containing lysozyme and oligosaccharide and application thereof
CN106667915B (en) It is a kind of for treating the scutelloside aluminium dry suspensoid agent of grice diarrhoea
CN103083348A (en) Albendazole/ivermectin powder for livestock
CN102512386A (en) Amoxicillin or amoxicillin and clavulanate potassium instant chewable tablets for pet and preparation method for same
CN102860984B (en) Method for preparing compound sulfachloropyridazine sodium powder
CN103083347B (en) Preparation method of albendazole/ivermectin powder for livestock
CN102283842A (en) Compound mequindox florfenicol nanoemulsion antibacterial drug and preparation method thereof
CN102406613B (en) Super tylosin soluble powder and preparation method thereof
CN103126982A (en) Novel veterinary medicament meglumine enrofloxacin injection and preparation method thereof
CN103536604B (en) A kind of wettable sulfamethoxazole trimethoprim powder and preparation method thereof
CN103536602B (en) Medicine used for controlling pasteurella infection of livestock and poultry
CN103536601B (en) Preparation method of medicine used for controlling pasteurella infection of livestock and poultry
CN110251481A (en) A kind of veterinary tilmicosin taste masking slow-releasing granules and its preparation process
CN110179756A (en) A kind of tilmicosin micro-capsule preparation and preparation method thereof
CN103520267A (en) Wettable experimental pullorum evapotranspiration and preparation method thereof
CN105919960B (en) A kind of roxithromycin dispersing tablet and preparation method thereof
CN103721240A (en) Compound formulation for treating bacterial infection of digestive tract of livestock and poultry and preparation method of compound formulation
CN102813909A (en) Compound doxycycline hydrochloride composition for preventing and treating colibacillosis and chronic respiratory disease of poultry as well as preparation method thereof
CN103536603A (en) Wettable sulfamonomethoxine (sodium) powder and preparation method thereof
CN103536606B (en) A kind of wettable sulfamethoxydiazine powder and preparation method thereof
CN114515274A (en) Acidified amoxicillin soluble powder and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131016

Termination date: 20150924

EXPY Termination of patent right or utility model